NCT06243484

Effect of the Food Supplement TOTUM-070 on Lipid Metabolism

Name: Clinical Trial NCT06243484
Creator: Valbiotis
Keywords: Hypercholesterolemia, TOTUM-070, dietary supplement, clinical trial, Germany

Clinical Study to Investigate the Effect of the Food Supplement TOTUM-070 on Lipid Metabolism in Moderately Hypercholesterolemic Subjects After 3 Months of Supplementation

Valbiotis·ClinicalTrials.gov·dietary supplementRecruiting

View on ClinicalTrials.gov →

Study focus

Disease/Condition: Hypercholesterolemia
Drug/Device/Intervention: TOTUM-070
Study type: Interventional
Intervention type: dietary supplement

Sponsor & location

Primary sponsor: Valbiotis
Location: Esslingen, Germany

Timeline & enrollment

Phase: N/A
Start date: Oct 04, 2023
End date: Apr 30, 2025
Enrollment: 180 participants

Primary outcome

Evolution of fasting blood LDL cholesterol level

Summary

This clinical trial is to confirm the effects of TOTUM-070, a mix of 5 plants extracts, consumed at the daily regimen of two times per day, on fasting blood LDL cholesterol concentrations in moderately hypercholesterolemic subjects after 12 weeks of consumption (V3).

ICD-10 classifications

Pure hypercholesterolaemiaLipoprotein deficiencyHyperglycaemia, unspecifiedDisorders of lipoprotein metabolism and other lipidaemiasOther disorders of lipoprotein metabolism

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT06243484
Type: Non-Device Trial

About this record

Access comprehensive clinical trial information for NCT06243484 through Pure Global AI's free database. This phase not specified trial is sponsored by Valbiotis and is currently Recruiting. The study focuses on Hypercholesterolemia. Target enrollment is 180 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.